Inhibikase Therapeutics, Inc. (IKT) Scientific Publications

Inhibikase Therapeutics, Inc. (IKT) Scientific Publications https://www.inhibikase.com/scientific-publications/rss en-us https://d1io3yog0oux5.cloudfront.net/inhibikase/files/theme/images/logo-sm.png Inhibikase Therapeutics, Inc. Logo https://www.inhibikase.com Equisolve Investor Relations Suite <![CDATA[A Phase I, Randomized, SAD, MAD, and PK Study of Risvodetinib in Older Adults and Parkinson’s Disease]]> https://d1io3yog0oux5.cloudfront.net/_309cfd86192644e4a3ea5a3761eb78f2/inhibikase/files/pages/inhibikase/db/1005/description/jpd_2024_14-2_jpd-14-2-jpd230319_jpd-14-jpd230319.pdf Tue, 19 Mar 24 00:00:00 -0400 https://d1io3yog0oux5.cloudfront.net/_309cfd86192644e4a3ea5a3761eb78f2/inhibikase/files/pages/inhibikase/db/1005/description/jpd_2024_14-2_jpd-14-2-jpd230319_jpd-14-jpd230319.pdf <![CDATA[The c-Abl inhibitor Risvodetinib (IkT-148009) suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson’s disease]]> https://www.science.org/doi/10.1126/scitranslmed.abp9352?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed Wed, 18 Jan 23 00:00:00 -0500 https://www.science.org/doi/10.1126/scitranslmed.abp9352?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed <![CDATA[MDS Congress 2022 - Risvodetinib (IkT-148009) as a potential disease-modifying therapy in Parkinson's disease]]> https://youtu.be/aQfvVEXgmfc Fri, 16 Sep 22 00:00:00 -0400 https://youtu.be/aQfvVEXgmfc <![CDATA[MDS Congress 2022 - Parkinson's disease modification through c-Abl inhibition]]> https://youtu.be/a6w_5DDcN-I Fri, 16 Sep 22 00:00:00 -0400 https://youtu.be/a6w_5DDcN-I <![CDATA[MDS Congress 2022 - Upcoming studies on Risvodetinib (IkT-148009) in MSA]]> https://youtu.be/aQfvVEXgmfc Fri, 16 Sep 22 00:00:00 -0400 https://youtu.be/aQfvVEXgmfc <![CDATA[MDS Congress 2022 Poster]]> https://d1io3yog0oux5.cloudfront.net/inhibikase/files/pages/inhibikase/db/1005/description/789-InhibikaseTherapeuticsrev.pdf Fri, 16 Sep 22 00:00:00 -0400 https://d1io3yog0oux5.cloudfront.net/inhibikase/files/pages/inhibikase/db/1005/description/789-InhibikaseTherapeuticsrev.pdf <![CDATA[Parkinson’s Disease Modification through Abl Kinase Inhibition: An Opportunity]]> https://d1io3yog0oux5.cloudfront.net/_5ce61bdbf47e2aa9222f22a00e250d0d/inhibikase/db/924/7582/file/17248291.pdf Mon, 01 Nov 21 00:00:00 -0400 https://d1io3yog0oux5.cloudfront.net/_5ce61bdbf47e2aa9222f22a00e250d0d/inhibikase/db/924/7582/file/17248291.pdf <![CDATA[Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease]]> https://d1io3yog0oux5.cloudfront.net/_5ce61bdbf47e2aa9222f22a00e250d0d/inhibikase/db/924/7545/file/MSA-NBD.pdf Sun, 01 Nov 20 00:00:00 -0400 https://d1io3yog0oux5.cloudfront.net/_5ce61bdbf47e2aa9222f22a00e250d0d/inhibikase/db/924/7545/file/MSA-NBD.pdf <![CDATA[Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s disease]]> https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6706297/ Sat, 01 Aug 20 00:00:00 -0400 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6706297/ <![CDATA[Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson’s disease]]> https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658849/ Thu, 01 Aug 19 00:00:00 -0400 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658849/